E-mail us: service@prospectnews.com Or call: 212 374 2800
Bank Loans - CLOs - Convertibles - Distressed Debt - Emerging Markets
Green Finance - High Yield - Investment Grade - Liability Management
Preferreds - Private Placements - Structured Products
 
Published on 5/28/2013 in the Prospect News Investment Grade Daily.

New Issue: Pfizer taps market for $4 billion of notes in five tranches

By Andrea Heisinger

New York, May 28 - Pfizer Inc. priced $4 billion of notes (A1/AA/A+) in five tranches during Tuesday's session, a source close to the trade said.

The sale included $750 million of 0.9% notes due January 2017 priced at 99.84 to yield 0.945% with a spread of Treasuries plus 45 basis points. Initial guidance was in the high 40 bps area.

The notes carry a make-whole call at Treasuries plus 10 bps.

There was $500 million of five-year floating-rate notes sold at par to yield Libor plus 30 bps.

The company also priced $1 billion of 1.5% five-year fixed-rate notes at 99.942 to yield 1.512% with a spread of Treasuries plus 50 bps. Talk was initially in the low 50 bps area.

The tranche has a make-whole call at Treasuries plus 10 bps.

A $1 billion tranche of 3% 10-year notes sold at 99.681 to yield 3.035% with a spread of Treasuries plus 87.5 bps. Guidance was in the low 80 bps area.

There is a make-whole call at 15 bps over Treasuries.

Finally, there was $750 million of 4.3% 30-year bonds priced at 99.781 to yield 4.313% with a spread of 100 bps over Treasuries. Initial talk was in the 100 bps area.

The bonds have a make-whole call at 15 bps over Treasuries.

Bookrunners were Citigroup Global Markets Inc., Credit Suisse Securities (USA) LLC, Goldman Sachs & Co. and RBS Securities Inc.

Proceeds will be used for general corporate purposes, including repayment at maturity of €1.85 billion 3.625% notes due in June, and to prefund repayment of a portion of outstanding 4.5% notes due in February 2014 and 5.5% notes due in February 2014.

The New York-based global biopharmaceutical company was last in the U.S. bond market with a $13.5 billion offering in five tranches on March 17, 2009.

Issuer:Pfizer Inc.
Issue:Notes
Amount:$4 billion
Bookrunners:Citigroup Global Markets Inc., Credit Suisse Securities (USA) LLC, Goldman Sachs & Co., RBS Securities Inc.
Trade date:May 28
Ratings:Moody's: A1
Standard & Poor's: AA
Fitch: A+
Notes due 2017
Amount:$750 million
Maturity:Jan. 15, 2017
Coupon:0.9%
Price:99.84
Yield:0.945%
Spread:Treasuries plus 45 bps
Call:Make-whole at Treasuries plus 10 bps
Price talk:High 40 bps area
Five-year notes
Amount:$1 billion
Maturity:June 15, 2018
Coupon:1.5%
Price:99.942
Yield:1.512%
Spread:Treasuries plus 50 bps
Call:Make-whole at Treasuries plus 10 bps
Price talk:Low 50 bps area
Five-year floaters
Amount:$500 million
Maturity:June 15, 2018
Coupon:Libor plus 30 bps
Price:Par
Yield:Libor plus 30 bps
Call:Non-callable
Price talk:Libor equivalent to five-year fixed rates notes
10-year notes
Amount:$1 billion
Maturity:June 15, 2023
Coupon:3%
Price:99.681
Yield:3.035%
Spread:Treasuries plus 87.5 bps
Call:Make-whole at Treasuries plus 15 bps
Price talk:High 80 bps area
30-year bonds
Amount:$750 million
Maturity:June 15, 2043
Coupon:4.3%
Price:99.781
Yield:4.313%
Spread:Treasuries plus 100 bps
Call:Make-whole at Treasuries plus 15 bps
Price talk:100 bps area

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.